Retatrutide phase 3 results: what the 2026 readouts say
Last updated November 10, 2026
In July 2026 the developer of the triple agonist reported two more phase 3 trials. Both met their main goal at 80 weeks.
TRIUMPH-2: obesity with type 2 diabetes
1,152 adults. Average weight change at 80 weeks was -12.7%, -19.1% and -20.8% on 4, 9 and 12 mg, against -4.0% on placebo. People with type 2 diabetes usually lose less on these drugs, so 20.8% drew attention.
TRIUMPH-3: severe obesity with heart disease
1,949 adults with a BMI of 35 or more and established cardiovascular disease. Average change was -21.6% on 9 mg and -22.6% on 12 mg, against -3.2% on placebo.
Safety
Side effects were mostly digestive. In TRIUMPH-3, 13.5% of the 12 mg group stopped treatment because of side effects against 4.8% on placebo. Altered skin sensation was reported by roughly 6% on the drug against 1.3% on placebo.
What happens next
The company says it plans to file with the FDA in the first quarter of 2027. Until there is a decision the molecule stays investigational. The research compound GLP-3RT is a laboratory chemical, not the trial drug.